Breast Cancer Quiz: Trivia Questions! Test

Preferred for Stage I and Stage II breast cancer.

Estrogen Receptor/Progesterone Receptor (ER/PR) positive tumors are more common in postmenopausal women. The response shows a more favorable prognosis.

It is 85-90% of breast cancer cases.

Patients with Stage IV breast cancer typically develop resistance to endocrine therapy over time. Endocrine therapy targets hormone receptors in cancer cells, but eventually, cancer cells can become resistant to this type of treatment. When resistance occurs, switching the patient to chemotherapy is often recommended. Chemotherapy uses drugs to kill or slow the growth of cancer cells and can be effective in managing Stage IV breast cancer after endocrine therapy resistance has developed. Therefore, the statement "we should switch the patient to chemotherapy" is true.

Neoadjuvant therapy is used to debulk the tumor for a more successful surgery.

Younger patients may need an ultrasound or MRI to confirm a tumor.

In Stage IV breast cancer, the cancer has spread to other parts of the body, such as the bones, lungs, or liver. At this stage, the goal of treatment shifts from curing the cancer to managing the symptoms, improving quality of life, and prolonging survival. While treatment options are available to control the disease and provide relief, complete eradication of the cancer is generally not achievable. Therefore, the statement that cure is no longer a goal in Stage IV breast cancer is true.

The statement is true because the type of surgery a patient undergoes for breast cancer does not affect their survival rate. Whether they choose a full mastectomy, a segmental or partial mastectomy, or a lumpectomy, the survival outcome remains the same. Therefore, the decision on which surgery to pursue is based on the patient's preference.

Nonproliferative has no change in risk and proliferative, no atypia only has a slight increase of 1.2-2x.

Trastuzumab should always be added to HER2 positive tumors. If the tumor is > 2cm or there are positive lymph nodes, pertuzumab should be considered.

All of these are used to aid in treatment decisions.

The correct daily dosing for Tamoxifen is 20mg PO. PO stands for "per os" which means it should be taken orally. Tamoxifen is commonly prescribed for the treatment of breast cancer and is usually taken once daily. The dosage of 20mg is the standard recommended dose for most patients.

If anything it just adds more cost and side effects.

Can occur months later, patient needs to hydrate and urinate frequently.

The correct answer is ages 40 and above are annually. According to the NCCN guidelines, women aged 40 and above should get mammograms every year. This is to ensure early detection of breast cancer and increase the chances of successful treatment. Regular mammograms are especially important as women age, as the risk of developing breast cancer increases. Therefore, it is recommended that women aged 40 and above undergo annual mammograms.

Breast-conserving therapy (BCT) must always be followed with radiation due to a higher incidence of local recurrence. Types of BCT include a segment or partial mastectomy and lumpectomy.

The correct answer is "After chemotherapy" because Tamoxifen is a hormonal therapy commonly used in the treatment of hormone receptor-positive (ER+ and/or PR+) breast cancer. It works by blocking the effects of estrogen on breast cancer cells. Chemotherapy is typically given before hormonal therapy to shrink tumors and kill cancer cells, so it is important to complete chemotherapy before starting Tamoxifen.

Previous chest irradiation is a risk factor. Increasing age is a risk factor.

They should always receive endocrine therapy AFTER chemo.

A tumor that is less than 2cm in size and has no axillary node involvement has a favorable prognosis. This means that the tumor is relatively small and has not spread to the lymph nodes, indicating a lower likelihood of metastasis and better chances of successful treatment and survival.

A tumor that is larger than 5cm and has no axillary involvement has a poorer prognosis. This means that when the tumor size exceeds 5cm and there is no spread to the axillary lymph nodes, the chances of a more negative outcome or prognosis for the patient are higher. The size of the tumor plays a significant role in determining the severity and aggressiveness of the cancer, and when it surpasses 5cm, it indicates a more advanced stage of the disease.

Only monthly dosing can guarantee ovarian suppression.

If a patient is young age and has a family history of breast cancer, consider genetic testing.

The number of involved axillary lymph nodes is the most important prognostic factor.

NCCN recommends clinical breast exams from ages 25 to 40 every 1 to 3 years and annually after the age of 40.

Aromatase inhibitors should not be used alone for this patient.

Carboplatin is included in therapy for HER-2/neu + patients because HER-2/neu is a protein that promotes the growth of cancer cells. Carboplatin is a chemotherapy drug that works by interfering with the DNA in cancer cells, preventing them from growing and dividing. Therefore, it is used specifically in patients who have HER-2/neu positive breast cancer to target and inhibit the growth of these cancer cells.

1-3 nodes involved has a better prognosis whereas 4+ nodes involved has a poorer prognosis.

Delayed cardiotoxicity is the DLT and HMT. Baseline EF should be obtained prior to therapy. There are lifetime maximum doses.

AI therapy is preferred over Letrozole + Palbociclib because we don't know how that therapy actually affects survival.

USPTF has no comment on breast awareness.

Anthracycline-containing regimens may be MORE effective in HER-2/neu+ patients.

Patients receiving Pamidronate therapy should be counseled to take daily calcium and vitamin D supplementation to prevent bone loss. They should also undergo a dental exam before starting the therapy and avoid any dental procedures while using the medication, as Pamidronate can cause jaw problems. The data suggests that this drug can be used for up to 2 years, but longer use may also provide benefits.

Although lumpectomy with XRT (radiotherapy) is preferred, the patient could also have a mastectomy or lumpectomy followed by observation.

Edema is the HMT for Docetaxel

Eribulin can be used for taxane resistance.

The patient can either switch or remain on tamoxifen, but they need to be on the therapy for a total of 10 years.

The ACS guidelines recommend that women aged 40 to 44 have the option to get mammograms every 1 year. For women aged 45 to 54, the guidelines recommend getting mammograms annually. Women over the age of 55 are advised to get mammograms every 2 years. Therefore, the correct answer includes these recommendations from the ACS guidelines.

The correct answer is a combination of aromatase inhibitor therapy for 5 years and tamoxifen therapy for a total of 10 years. This is because adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer typically involves a sequence of these two types of medications. Aromatase inhibitors are initially used for 5 years to block the production of estrogen, followed by tamoxifen therapy for an additional 5 years to further reduce the risk of recurrence. In some cases, tamoxifen therapy may be given first for 2-3 years, followed by aromatase inhibitor therapy for a total duration of 10 years.

The USPTF screening recommendations suggest that women between the ages of 40 to 49 should make an individual decision regarding mammograms. However, for women aged 50 to 74, it is recommended that they get a mammogram every year.

Venlafaxine, Citalopram, Escitalopram, and Sertraline are safe to take with Tamoxifen because they do not significantly interact with the drug and are not known to increase the risk of adverse effects or decrease the effectiveness of Tamoxifen. However, caution should still be exercised and it is always recommended to consult with a healthcare professional before starting any new medication. Fluoxetine and Paroxetine, on the other hand, may interact with Tamoxifen and should be avoided or used with caution under medical supervision.